Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 01, 2019 08:00 ET | Source: Chiasma, Inc.

Chiasma Supports Acromegaly Awareness Day

WALTHAM, Mass., Nov. 01, 2019 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic...
October 29, 2019 08:00 ET | Source: Chiasma, Inc.

Chiasma to Report Third Quarter Financial Results on November 5, 2019

WALTHAM, Mass., Oct. 29, 2019 (GLOBE NEWSWIRE) -- Chiasma, Inc. (Nasdaq: CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic...
September 25, 2019 08:00 ET | Source: Chiasma, Inc.

Chiasma to Present at the Cantor 2019 Global Healthcare Conference

WALTHAM, Mass., Sept. 25, 2019 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic...
September 05, 2019 16:05 ET | Source: Chiasma, Inc.

Chiasma Hosting Key Opinion Leader Meeting on Maintenance Therapy of Adult Patients with Acromegaly

WALTHAM, Mass., Sept. 05, 2019 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic...
September 05, 2019 08:00 ET | Source: Chiasma, Inc.

Chiasma to Present at the H.C. Wainwright 21st Annual Global Investment Conference

WALTHAM, Mass., Sept. 05, 2019 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic...
August 08, 2019 16:05 ET | Source: Chiasma, Inc.

Chiasma Reports Second Quarter 2019 Results

Announces positive data from Phase 3 CHIASMA OPTIMAL trial; MYCAPSSA® NDA submission expected by year-end 2019 with an expected six-month PDUFA review time period MPOWERED enrollment complete;...
August 01, 2019 16:05 ET | Source: Chiasma, Inc.

Chiasma to Report Second Quarter Financial Results on August 8, 2019

WALTHAM, Mass., Aug. 01, 2019 (GLOBE NEWSWIRE) -- Chiasma, Inc. (Nasdaq: CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic...
July 26, 2019 09:06 ET | Source: Chiasma, Inc.

Chiasma Announces Pricing of Underwritten Public Offering of $55.0 Million of Common Stock

WALTHAM, Mass., July 26, 2019 (GLOBE NEWSWIRE) -- Chiasma, Inc. (Nasdaq: CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic...
July 25, 2019 16:01 ET | Source: Chiasma, Inc.

Chiasma Announces Proposed Offering of Common Stock

WALTHAM, Mass., July 25, 2019 (GLOBE NEWSWIRE) -- Chiasma, Inc. (Nasdaq: CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic...
July 23, 2019 06:00 ET | Source: Chiasma, Inc.

Chiasma Announces Positive Phase 3 Top-Line Results from CHIASMA OPTIMAL Clinical Trial of Mycapssa® for the Maintenance Treatment of Adults with Acromegaly

SPA-agreed trial met primary and all secondary endpoints No new or unexpected safety signals in the Mycapssa treated patients 90% of the patients treated with Mycapssa who completed the 36-week...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right